Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 7/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26098791 | 0.96 | NAMPT (0.57) | NAMPTHTTSMN1; SMN2KMT2AMAPT | |
| SCHEMBL23747749 | 0.90 | HTT (0.67) | NAMPTHTTSMN1; SMN2KMT2AMAPT | |
| SCHEMBL30361473 | 0.90 | HTT (0.67) | NAMPTHTTSMN1; SMN2KMT2AMAPT | |
| SCHEMBL23747747 | 0.89 | NAMPT (0.59) | NAMPTKMT2AMAPTMEN1POLB | |
| SCHEMBL26101596 | 0.87 | NAMPT (0.54) | NAMPTKMT2AMAPTMEN1POLB | |
| SCHEMBL12335089 | 0.85 | NPC1 (0.69) | NAMPTHTTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL12335076 | 0.85 | MEN1 (0.71) | NAMPTHTTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL23747379 | 0.82 | RAB9A (0.63) | NAMPTHTTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL20379441 | 0.82 | NAMPT (0.86) | NAMPTSMN1; SMN2KMT2AMEN1POLB | |
| SCHEMBL30361424 | 0.81 | NAMPT (0.66) | NAMPTKMT2AMEN1POLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2021159015-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133132-A1 | NAMPT MODULATORS | NAMPT, MC4R, SIRT1 | NAMPT 1/4885HTT 1174/4885SMN1; SMN2 1161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.